These findings suggest that targeting CA2 PNNs offers a promising avenue for therapeutic intervention to combat age‐related cognitive decline, with implications for conditions like Alzheimer's disease and other neurodegenerative disorders. This evidence concerns the gene CA2 and early-onset autosomal dominant Alzheimer disease.